Articles

Discarding DMSO

First viable, non-DMSO umbilical cord graft to debut at the NY20 Foundation for Podiatric Medicine meeting
Brought to you byDDNews Staff
| 2 min read

HACKENSACK, N.J.—Royal Biologics has announced the launch of Cryo-Cord, reportedly the first viable, dimethyl sulfoxide (DMSO)-free umbilical cord graft. The company will showcase Cryo-Cord, along with its new portfolio of Autologous Live Cellular (ALC) technologies, at the NY20 Foundation for Podiatric Medicine meeting, held January 24-26 in New York, N.Y.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.